Growth Hormone Market By Indications (Growth Hormone Deficiency (GHD), Turner Syndrome, & Prader-Willi Syndrome), Administrative Route (Subcutaneous, Intramuscular, & Hospital Pharmacies), Channel Distribution (Hospital Pharmacies, Retail Pharmacies/Drug Stores, & Online pharmacies), & Region for 20

Growth Hormone Market Valuation – 2024-2031

The growth hormones growing awareness and their greater use in treating illnesses involving hormonal imbalance are among the reasons driving the market’s expansion. Major R&D projects are being carried out by top pharmaceutical and biopharmaceutical businesses in an attempt to commercialize new hormone therapy. These treatments seek to offer improved safety profiles and long-term activity, which will further propel the market’s global expansion. The market size surpass USD 4.75 Billion valued in 2024 to reach a valuation of around USD 7.66 Billion by 2031.

The need for hormone treatments has increased due to the rising prevalence of growth hormone shortages brought on by genetic illnesses, brain traumas, congenital abnormalities, and some medicinal procedures. In the UK, 1 in every 3,500–4,000 children are diagnosed with pediatric growth hormone insufficiency, according to the NCBI. The growth hormone industry is also expanding as a result of continuous research and development efforts in this domain. The rising demand for growth hormones is enabling the market grow at a CAGR of 6.80% from 2024 to 2031.

Growth Hormone MarketDefinition/ Overview

An essential peptide hormone for human development, human growth hormone (hGH), sometimes referred to as somatotropin, is in charge of cell division, regeneration, and growth stimulation. The incapacity of the pituitary gland to produce growth hormone (GH) leads to a growth hormone shortage. Humans can also have growth hormone insufficiency due to a number of hereditary disorders, such as Prader-Willi syndrome, Turner syndrome, and idiopathic short stature (ISS), which results in delayed puberty and shorter-than-average height.

Nowadays, older folks, bodybuilders, and athletes commonly abuse human growth hormone (hGH) as an anabolic drug for performance enhancement and as an anti-aging treatment. Since growth hormone is a restricted chemical, the USFDA has not approved it for use in anti-aging or performance-enhancing applications. Growth hormone medications are appropriate short-term therapies for these disorders, which are increasingly widespread globally in both young and old persons. Human growth hormone medication is widely accessible on the market these days, increasing knowledge of its health benefits and assisting manufacturing corporations in generating more income.

Will the Increasing Prevalence of Growth Hormone Deficiency (GHD) Globally Propel the Growth Hormone Market?

The increasing global frequency of Growth Hormone Deficiency (GHD) is expected to drive the growth hormone market. Growth hormone shortage is a disorder in which the pituitary gland does not secrete enough growth hormone. It affects both children and adults. Better diagnostic procedures, improved awareness, and increasing rates of genetic diseases and endocrine problems all contribute to GHD’s rising incidence. As more people are diagnosed with GHD, there is an increasing demand for effective treatments, notably recombinant human growth hormone (rhGH) therapies, which are critical for treating the condition. This rising patient base needs continual therapy innovations, which drive the growth hormone market.

Advances in biotechnology and pharmaceutical research have resulted in the creation of more effective and patient-friendly growth hormone formulations, such as long-acting GH preparations that lessen the need for injections. This breakthrough improves patient compliance and treatment outcomes, boosting the use of growth hormone therapy. Additionally, favorable government regulations, higher healthcare spending, and the presence of a solid pipeline of growth hormone medicines under development all contribute to market growth. Pharmaceutical firms are investing substantially in R&D to create new therapies and extend their product portfolios, which is expected to greatly boost the growth hormone market in the coming years.

Will the High-Cost Treatment Impact the Demand for Growth Hormone Market?

The high cost of treatment can have a substantial impact on the demand for growth hormones, albeit the effect is multidimensional. On the one hand, high treatment costs might limit access and affordability for a large number of patients, especially in areas with underdeveloped healthcare systems or limited insurance coverage. Patients who lack adequate health coverage or financial resources may be unable to afford these treatments, resulting in a decrease in overall demand. This is especially important in areas where out-of-pocket expenses are high or when government subsidies and insurance policies may not cover the whole cost of growth hormone therapy. As a result, the prospective patient base declines, affecting market growth negatively.

The high treatment cost can also be attributed to the large R&D spending required to create effective and safe growth hormone therapy. These treatments frequently require advanced biotechnological procedures and demanding regulatory approvals, which contributes to their expensive costs. Regardless of the expense, demand can remain strong in areas with well-established healthcare systems and significant insurance coverage, where a larger proportion of the population can afford such treatments.

Furthermore, advances in biotechnology and the introduction of biosimilars may gradually cut costs and increase affordability, thereby growing the market in the long term. Furthermore, if awareness of growth hormone deficits and associated treatments grows, and more efficient and cost-effective production methods are created, the industry may see stable or even growing demand despite the current high cost.

Category-Wise Acumens

Will the Well-Defined Diagnostic Criteria and Tests for Growth Hormone Deficiency (GHD) Drive the Segment of the Growth Hormone Market?

Well-defined diagnostic criteria and testing for growth hormone deficiency (GHD) are expected to drive the growth hormone market segment significantly. Clear and reliable diagnostic protocols ensure that GHD is detected quickly and correctly, allowing for appropriate intervention. This increases the number of instances diagnosed, hence extending the patient population eligible for growth hormone therapy. Improved diagnostics lower the likelihood of misdiagnosis and underdiagnosis, which have previously been hurdles to therapy. As healthcare professionals improve their ability to recognize and diagnose GHD using standardized tests, demand for growth hormone therapy is likely to increase, boosting market growth.

Advancements in diagnostic technologies improve the reliability and accessibility of GHD testing. More sensitive assays and advanced imaging techniques enable earlier and more precise detection of GHD. This not only helps to start treatment at the best time, but it also instills trust in healthcare professionals and patients about the efficacy and necessity of growth hormone therapy. Furthermore, the adoption of widely accepted diagnostic criteria speeds up the approval process for new therapies and promotes insurance coverage, making treatments more accessible and inexpensive. As a result, the growth hormone market segment benefits from increased adoption and use of these therapies, which are supported by well-defined and widely accepted diagnostic standards.

Will the Ease of Administration of Subcutaneous Injections Drive Significant Demand for Growth Hormone Market?

The convenience of administering subcutaneous injections is expected to fuel significant demand in the growth hormone industry. Subcutaneous injections, which are given beneath the skin, are often more convenient and less painful than intramuscular injections, making them more appealing to patients, particularly those who require long-term treatment, such as growth hormone therapy. The convenience of at-home administration eliminates the need for frequent hospital visits, easing the stress on both patients and healthcare staff. This ease of use increases patient compliance and adherence to the treatment regimen, which is critical to the efficacy of growth hormone therapy. As a result, more patients are likely to choose and adhere to growth hormone therapy, increasing demand.

Advancements in injectable technology, such as the introduction of pen injectors and auto-injectors, have streamlined the process, improving patient comfort and dosage accuracy. These devices are intended to be user-friendly, minimizing the anxiety and difficulty associated with traditional syringe injections. Pediatric patients, who account for a sizable share of the growth hormone market, benefit from the reduced pain and convenience of administration, prompting parents to pick these treatments for their children. Furthermore, the introduction of long-acting growth hormones that require fewer injections may increase market demand by enhancing patient convenience. Overall, the improved simplicity of administration via subcutaneous injections plays an important role in enhancing patient acceptance and market growth for growth hormone therapy.

Gain Access Growth Hormone Market Report Methodology

Country/Region-wise Acumens

Will Established Healthcare Infrastructure in North America Accelerate the Growth of Growth Hormone Market?

The developed healthcare infrastructure in North America is expected to accelerate the expansion of the growth hormone market. The region’s modern healthcare systems are distinguished by broad access to medical services, comprehensive insurance coverage, and significant government and private sector investment in healthcare. These characteristics ensure that patients who require growth hormone therapy have easier access to them than in regions with less developed healthcare infrastructures. Insurance plans and government programs in North America frequently pay a considerable amount of treatment costs, making it more accessible to patients and thus generating demand. Furthermore, the presence of specialized medical personnel and facilities capable of accurately diagnosing and managing growth hormone shortages helps to drive market expansion.

North America’s excellent healthcare system enables extensive pharmaceutical and biotechnology research and development. This atmosphere encourages innovation and the ongoing development of new and improved growth hormone therapy. Pharmaceutical businesses in the region benefit from advantageous regulatory frameworks that speed up the approval and market introduction of innovative therapies. The availability of enhanced diagnostic tools and tailored medical approaches improves the efficacy and acceptability of growth hormone treatments. These features, together with a high degree of health awareness in the population, provide a consistent and growing demand for growth hormone treatments, hastening the market’s rise in North America.

Will Rising Disposable Income, Drive the Growth Hormone Market in Asia Pacific Region?

Rising disposable income will greatly boost the Asia Pacific growth hormone market. As disposable incomes rise, more people may purchase previously inaccessible healthcare services and treatments. This economic shift makes modern medical procedures, such as growth hormone treatments, more accessible to a larger segment of the population. Higher disposable income also allows families to prioritize healthcare spending, increasing demand for treatments that address growth hormone deficits in children and adults. Furthermore, with greater financial stability, people are more likely to choose preventive and long-term health solutions, such as regular and expensive therapies like growth hormone therapy.

Rising disposable income is frequently associated with increased healthcare infrastructure and access to higher-quality facilities. Governments in the Asia Pacific area are anticipated to invest more in healthcare systems as economic growth and revenue increase, making modern treatments more accessible. As a result, knowledge of growth hormone deficits and treatment options are projected to increase. Pharmaceutical businesses are also likely to expand their operations and marketing activities in these areas, anticipating increased demand. The growth hormone market in the Asia Pacific region is poised for significant increase, thanks to ongoing biotechnology developments and the launch of cost-effective biosimilars. Rising disposable incomes make these treatments more accessible to a larger population.

Competitive Landscape

The growth hormone market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the market include

• Eli Lilly and Company
• Pfizer Inc.
• Merck & Co., Inc.
• Novo Nordisk A/S
• Roche Holding AG
• Genetech, Inc. (A subsidiary of Roche Holding AG)
• Jiangsu Hengrui Medicine Co., Ltd.
• Zhengzhou Beitong Pharmaceutical Co., Ltd.
• LG Chem, Ltd.

Latest Developments

• In August 2023, the FDA authorized Opko Health, Inc. and Pfizer’s once-weekly somatrogon for children with growth hormone shortage, and prominent players are strategically expanding their market position. According to phase 3 trial data, the long-acting injectable Somatrogon-gala (Ngenla) performs similarly to somatropin in terms of enhancing annual height velocity. This approval, which shares a comparable safety profile to somatropin, underscores Opko Health and Pfizer’s commitment to addressing growth failure in children through novel pharmacological treatments.
• In May 2023, Novo Nordisk advanced in the human growth hormone therapy market with a positive statement from the European Medicines Agency, which recommended once-weekly Sogroya for children aged three and above, addressing growth hormone insufficiency and development failure in teenagers.
• In February 2022, OPKO and Pfizer received European Union marketing approval for their once-weekly NGENLA (somatrogon) Injection, which is intended to treat juvenile growth hormone insufficiency.

Report Scope

Growth Hormone Market, By Category

Indications

• Growth Hormone Deficiency (GHD)
• Turner Syndrome
• Prader-Willi Syndrome
• Chronic Kidney Disease (CKD)
• Short Stature Associated with Idiopathic Short Stature (ISS)

Administrative Route

• Subcutaneous
• Intramuscular
• Hospital Pharmacies
• Retail Pharmacies/Drug Stores
• Online pharmacies

Channel Distribution

• Hospital Pharmacies
• Retail Pharmacies/Drug Stores
• Online pharmacies

Region

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any  please connect with our sales team, who will ensure that your requirements are met.